Lifesci Capital Comments on Perspective Therapeutics Q2 Earnings

Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) – Research analysts at Lifesci Capital issued their Q2 2026 EPS estimates for shares of Perspective Therapeutics in a research report issued to clients and investors on Tuesday, May 12th. Lifesci Capital analyst O. Mccammon forecasts that the company will post earnings per share of ($0.29) for the quarter. The consensus estimate for Perspective Therapeutics’ current full-year earnings is ($1.17) per share. Lifesci Capital also issued estimates for Perspective Therapeutics’ Q3 2026 earnings at ($0.31) EPS, Q4 2026 earnings at ($0.32) EPS and FY2026 earnings at ($1.27) EPS.

Perspective Therapeutics (NYSEAMERICAN:CATX) last released its earnings results on Monday, May 11th. The company reported ($0.25) EPS for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.04. The company had revenue of $0.08 million during the quarter, compared to analysts’ expectations of $0.16 million. Perspective Therapeutics had a negative net margin of 17,982.69% and a negative return on equity of 47.18%.

Several other analysts also recently weighed in on CATX. B. Riley Financial boosted their price target on Perspective Therapeutics from $11.00 to $13.00 and gave the company a “buy” rating in a research note on Wednesday, March 18th. Royal Bank Of Canada dropped their price target on Perspective Therapeutics from $18.00 to $14.00 and set an “outperform” rating on the stock in a research note on Tuesday, March 17th. HC Wainwright boosted their price objective on Perspective Therapeutics from $12.00 to $13.00 and gave the company a “buy” rating in a report on Monday, March 23rd. Piper Sandler started coverage on Perspective Therapeutics in a report on Thursday, February 19th. They issued an “overweight” rating and a $16.00 price objective for the company. Finally, Truist Financial set a $12.00 price objective on Perspective Therapeutics in a report on Tuesday, March 17th. One equities research analyst has rated the stock with a Strong Buy rating and eight have given a Buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $12.63.

Perspective Therapeutics Stock Performance

Perspective Therapeutics stock opened at $3.77 on Wednesday. The company has a current ratio of 5.17, a quick ratio of 5.17 and a debt-to-equity ratio of 0.01. The business’s 50-day simple moving average is $4.47 and its two-hundred day simple moving average is $3.59. Perspective Therapeutics has a fifty-two week low of $1.96 and a fifty-two week high of $6.16.

Hedge Funds Weigh In On Perspective Therapeutics

A number of hedge funds have recently made changes to their positions in CATX. Opaleye Management Inc. acquired a new position in shares of Perspective Therapeutics during the fourth quarter valued at approximately $3,257,000. Patient Square Capital LP grew its position in shares of Perspective Therapeutics by 224.3% in the fourth quarter. Patient Square Capital LP now owns 1,132,815 shares of the company’s stock valued at $3,115,000 after purchasing an additional 783,492 shares in the last quarter. Bank of America Corp DE grew its position in shares of Perspective Therapeutics by 139.9% in the third quarter. Bank of America Corp DE now owns 785,823 shares of the company’s stock valued at $2,695,000 after purchasing an additional 458,323 shares in the last quarter. Marshall Wace LLP purchased a new stake in shares of Perspective Therapeutics in the fourth quarter valued at approximately $1,119,000. Finally, JPMorgan Chase & Co. grew its position in shares of Perspective Therapeutics by 118.4% in the second quarter. JPMorgan Chase & Co. now owns 748,067 shares of the company’s stock valued at $2,573,000 after purchasing an additional 405,612 shares in the last quarter. Institutional investors and hedge funds own 54.66% of the company’s stock.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.